cvac production capacity and facility., page-9

kbear1...not sure where I went wrong here.

From the PRR web site
http://www.primabiomed.com.au/trail/patient_access.php

"The vaccine therapy uses special cells called dendritic cells, taken from the ovarian cancer patient's blood by a process called leukapheresis. The patient's blood is circulated through a special filter that takes out only the dendritic cells needed to make the vaccine. These cells are multiplied in the laboratory, and then bathed with a protein called mucin-1 which is present in great amounts in the tumors cells. The dendritic cells take up the mucin-1, and are then frozen to be shipped to the physician for administration to the patient. The vaccine is thawed, then injected into the surface of the skin. Once in the skin the dendritic cells activate immune cells called T Cells and program them to find and destroy tumour cells producing the mucin-1 protein."

So...I was thinking...

scenario 1....Dubai takes the patients blood and ships it off for treatment, and later receives the frozen treated blood for the patients treatment schedule. (as above)

scenario 2....Dubai completes a manufacturing facility, receives patients blood from elsewhere (Oz, Europe, USA etc), treats the blood and sends it back to the overseas patient...charges some amount for this service, and probably pays a small royalty to PRR